IPSC
Company Description
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 109.16M | 6.59M | 2.23M | 5.20M | 0 | 0 | 0 |
| Net Income | (9.58M) | (126.57M) | (136.67M) | (130.93M) | (95.82M) | (53.58M) | (244.77M) |
| EPS | -0.11 | -1.61 | -2.30 | -2.27 | -1.74 | -1.00 | -4.49 |
| Free Cash Flow | (104.72M) | (110.29M) | (102.08M) | (16.55M) | (133.97M) | (51.09M) | (18.63M) |
| FCF / Share | -1.21 | -1.40 | -1.72 | -0.29 | -2.44 | -0.93 | -0.34 |
| Operating CF | (103.88M) | (110.14M) | (88.35M) | 14.05M | (89.00M) | (41.27M) | (16.17M) |
| Total Assets | 223.70M | 353.22M | 360.69M | 486.54M | 437.38M | 106.78M | 90.90M |
| Total Debt | 43.56M | 53.83M | 48.17M | 49.41M | 25.12M | 21.55M | 0 |
| Cash & Equiv | 61.85M | 58.44M | 47.32M | 84.27M | 56.45M | 27.21M | 44.06M |
| Book Value | 158.94M | 161.36M | 184.75M | 302.74M | 396.24M | (106.41M) | (91.86M) |
| Return on Equity | -0.06 | -0.78 | -0.74 | -0.43 | -0.24 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 109.16M | 4.17M | 791,000 | 771,000 | 855,000 | 268,000 | 148,000 |
| Net Income | (34.55M) | (21.64M) | (19.17M) | (34.42M) | (32.54M) | 76.56M | (36.07M) | (31.23M) | (31.21M) | (28.06M) | (39.40M) | (32.72M) |
| EPS | -0.17 | -0.25 | -0.22 | -0.40 | -0.38 | 0.89 | -0.46 | -0.37 | -0.38 | -0.45 | -0.66 | -0.55 |
| Free Cash Flow | (20.53M) | (25.83M) | (16.39M) | (25.78M) | (27.91M) | (35.10M) | (24.38M) | (27.51M) | (27.60M) | (30.79M) | (27.21M) | (16.91M) |
| FCF / Share | -0.10 | -0.30 | -0.19 | -0.30 | -0.32 | -0.41 | -0.31 | -0.32 | -0.34 | -0.49 | -0.45 | -0.28 |
| Operating CF | (19.83M) | (25.24M) | (16.08M) | (25.58M) | (27.59M) | (34.62M) | (24.22M) | (28.33M) | (27.33M) | (30.25M) | (26.23M) | (13.65M) |
| Total Assets | 287.01M | 326.55M | 223.70M | 244.72M | 284.69M | 315.61M | 353.22M | 388.62M | 416.45M | 348.51M | 360.69M | 397.55M |
| Total Debt | 34.63M | 48.02M | 43.56M | 44.96M | 51.48M | 52.67M | 53.83M | 54.60M | 56.38M | 46.47M | 48.17M | 47.58M |
| Cash & Equiv | 49.64M | 51.05M | 61.85M | 55.52M | 56.88M | 51.87M | 58.44M | 52.59M | 41.46M | 46.81M | 47.32M | 55.31M |
| Book Value | 232.34M | 264.74M | 158.94M | 176.35M | 209.90M | 240.44M | 161.36M | 195.69M | 222.10M | 177.88M | 184.75M | 219.23M |
| Return on Equity | -0.15 | -0.08 | -0.12 | -0.20 | -0.16 | 0.32 | -0.22 | -0.16 | -0.14 | -0.16 | -0.21 | -0.15 |
